Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study

Maryam Kabootari1,2, Samaneh Asgari2, Seyedeh Maryam Ghavam3, Hengameh Abdi4, Fereidoun Azizi4 and Farzad Hadaegh2*

Abstract

Background: Fasting plasma glucose (FPG) and 2-h post challenge plasma glucose (2 h-PCPG), whether as continuous or categorical variables, are associated with incident cardiovascular disease (CVD) and diabetes; however, their role among patients with existing CVD is a matter of debate. We aimed to evaluate associations of different glucose intolerance states with recurrent CVD and incident diabetes among subjects with previous CVD.

Methods: From a prospective population-based cohort, 408 Iranians aged ≥ 30 years, with history of CVD and without known diabetes were included. Associations of impaired fasting glucose (IFG) according to the American Diabetes Association (ADA) and World Health Organization (WHO) criteria, impaired glucose tolerance (IGT), newly diagnosed diabetes (NDM) with outcomes of interest were determined by multivariable Cox proportional hazard models after adjustment for traditional risk factors. Furthermore, FPG and 2 h-PCPG were entered as continuous variables.

Results: Over a decade of follow-up, 220 CVD events including 89 hard events (death, myocardial infarction and stroke) occurred. Regarding prediabetes, only IFG-ADA was associated with increased risk of hard CVD [hazard ratio (HR), 95%CI: 1.62, 1.03–2.57] in the age-sex adjusted model. In patients with NDM, those with FPG ≥ 7 mmol/L were at higher risk of incident CVD/coronary heart disease (CHD) and their related hard outcomes (HR ranged from 1.89 to 2.84, all P < 0.05). Moreover, those with 2 h-PCPG ≥ 11.1 mmol/L had significant higher risk of CVD (1.46, 1.02–2.15) and hard CHD (1.95:0.99–3.85, P = 0.05). In the fully adjusted model, each 1 SD increase in FPG was associated with 20, 27, 15 and 25% higher risk of CVD, hard CVD, CHD and hard CHD, respectively; moreover each 1 SD higher 2 h-PCPG was associated with 21% and 16% higher risk of CVD, and CHD, respectively. Among individuals free of diabetes at baseline (n = 361), IFG-ADA, IFG-WHO and IGT were significantly associated with incident diabetes (all P < 0.05); significant associations were also found for FPG and 2 h-PCPG as continuous variables (all HRs for 1-SD increase > 2, P < 0.05).

Conclusions: Among subjects with stable CVD, NDM whether as high FPG or 2 h-PCPG, but not pre-diabetes status was significantly associated with CVD/CHD and related hard outcomes.

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Cardiovascular disease (CVD) is one of the high-burden diseases in the Middle East and North Africa (MENA) region and specially among Iranian population [1]. Individuals with history of CVD are at high risk of recurrent CVD events; traditional CVD risk factors, the number of stenotic coronaries, the presence of heart failure (HF), atrial fibrillation, cardiovascular treatment and geographic region have been reported as main determinants in international models for predicting recurrent CVD [2, 3].

Our previous study among patients with established CVD showed that type 2 diabetes is associated with > twofold higher risk of recurrent CVD events [4]. However, the impact of intensive glucose control versus appropriate management of blood pressure and lipid according to the guidelines on prevention of recurrent CVD in patients with diabetes are still inconclusive [5]. Impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes mellitus (NDM) with a high incidence rate among Iranian population [6, 7], are common disorders in patients with CVD [8]. Associations between prediabetes and NDM with recurrent CVD have been assessed in some short- and long-term hospital-based studies with inconsistent findings [9–12]; These studies were performed among patients with history of myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), HF [13] or history of acute coronary syndrome (ACS). According to these studies, Ryden et al. [14] strongly recommend using oral glucose tolerance test (OGTT) for all patients with coronary artery disease (CAD) without known dysglycemia to improve the prediction of recurrent CV events. However, recently, the investigators of ARTEMIS study [9] examined the prognostic significance of prediabetes among CAD patients in the stable phase of CAD. Findings showed that the presence of prediabetes, regardless of its definition, was not associated with higher incidence of major adverse cardiovascular events (MACE). To the best of our knowledge, this controversial issue has poorly been addressed in population-based studies, especially in regions with high burden of CVD [1].

In the current study, we aimed to investigate the associations between FPG and 2 h-post challenge plasma glucose (2 h-PCPG), whether as continuous or categorical variables, with subsequent CVD/coronary heart disease (CHD) events and related hard outcomes as well as incident type 2 diabetes among Iranian subjects with stable CVD and without known diabetes from the Tehran Lipid and Glucose Study (TLGS), the oldest population-based cohort of MENA region.

Materials and methods

Study population

The present study was conducted within the framework of the TLGS, an ongoing large prospective community-based study of a representative urban sample of Tehranian population with the aim of determining the prevalence and incidence of non-communicable diseases and related risk factors. Tehran is an ethnically diverse city. Population of Tehran comprises numerous ethnic, religious and linguistic groups, prominently including Persians, Azeris, Kurds, Lurs, Arabs, Baluchis, and Turkmen; 75% of people in Tehran identify themselves as Persian [15].

Briefly, participants have been recruited in first (1999–2001) and second (2002–2005) phases and follow-up visits has continued at approximately 3-year intervals, i.e. the third phase: 2005–2008, the fourth phase: 2009–2011, the fifth phase: 2012–2015 and the sixth phase: 2015–2018. Details of study design, sampling frame and rationale have been explained previously [16]. All participants gave written informed consents according to the Helsinki Declaration guideline and the study was approved by the local ethics committee (medical ethics committee of the Research Institute for Endocrine Sciences).

Outcome 1: recurrent CVD/CHD

In the present study, among 7116 participants aged ≥ 30 years, 547 participants with prevalent CVD were included [361 individuals from the study baseline (1999–2002) and 186 ones from the second phase (2002–2005)]. After excluding those with known diabetes (i.e. those taking glucose-lowering medications at baseline visit, n = 117), and those without any follow-up after the baseline recruitment (n = 22), 408 participants remained for the current study and were followed until March 2016 (overall response rate: 408/430 = 95%) (Fig. 1).

Outcome 2: type 2 diabetes

In the same data set, when considering incident diabetes as outcome, from the total of 547 participants with prevalent CVD, those on glucose-lowering medications at the baseline visit (n = 117) and those with NDM (n = 69) were excluded and 361 participants entered for data analysis (Fig. 1).
Clinical and laboratory measurements

Demographic information, medical history, smoking habits and history of CVD were obtained from participants during interviews, using a validated questionnaire at baseline and each follow-up. Details of anthropometric measurements including weight, height and waist circumferences (WC) have been described elsewhere [16]. Body mass index (BMI) was calculated as weight in kilograms divided by square of height (m²). Blood pressure (BP) was measured using a standardized mercury sphygmomanometer (calibrated by the Iranian Institute of Standards and Industrial Researches), twice on the right arm in a seated position after at least 15-min rest and the mean of these two measurements was considered as the participant’s BP.

Blood samples were taken between 7:00 and 9:00 AM after 12–14 h overnight fasting and a standard oral glucose tolerance test using 75 g glucose for those without history of taking glucose-lowering medications was performed. Details about measurements of serum glucose, total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) have been previously reported [16].

Definition of terms

For categorization of glucose tolerance status, we used both American Diabetes Association (ADA) [17] and World Health Organization (WHO) [18] criteria as follows: normal fasting glucose (NFG)-5.6: FPG < 5.6 mmol/L, NFG-6.1: FPG < 6.1 mmol/L, normal glucose tolerance (NGT): 2 h-PCPG < 7.8 mmol/L, IFG-ADA: 5.6 ≤ FPG < 7 mmol/L, IFG-WHO: 6.1 ≤ FPG < 7 mmol/L, IGT: 7.8 ≤ 2 h-PCPG < 11 mmol/L. NDM was defined as FPG ≥ 7.0 mmol/L or 2 h-PCPG ≥ 11.0 mmol/L at the first visit among those without history of taking glucose-lowering medications.

History of CVD was defined as history of ACS, definite coronary artery disease according to angiography results (>50% stenosis in at least one major coronary vessel), non-fatal MI, non-fatal stroke, CABG and PCI.

Positive family history of premature CVD was defined as history of CHD or stroke in a male
first-degree relative aged < 55 years or a female first-degree relative aged < 65 years. Positive family history of diabetes was determined as having at least a first-degree relative with diabetes. Smoking status was described as current smoker versus non-smoker. Hypertension was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or using anti-hypertensive drugs. Hypercholesterolemia was described as TC levels ≥ 5.1 mmol/L and/or using lipid lowering medications. Hypertriglyceridemia was defined as TG ≥ 1.69 mmol/L and low HDL-C as HDL-C < 1.06 mmol/L and < 1.29 mmol/L in men and women, respectively [19].

Outcomes
Detailed description of outcome data collection has been published previously [20]. Each participant in the TLGS is followed-up by telephone call from a trained nurse for any medical event leading to hospitalization during the past year; thereafter, a trained physician collects complementary data regarding that event during a home or hospital visit. In the case of mortality, data are collected from the hospital or death certificate by an authenticated local physician. Collected data is then evaluated by an outcome committee blinded to the status of baseline risk factors including the principal investigator, an internist, an endocrinologist, a cardiologist, an epidemiologist and other experts if needed to assign a specific outcome for every event.

In the current study, CHD events included cases of 1) definite MI [positive electrocardiogram (ECG) and biomarkers including creatine kinase (CK), CK-MB, troponin and myoglobin], 2) probable MI [positive ECG findings plus cardiac symptoms or signs and normal or equivocal biomarkers], 3) unstable angina pectoris (new cardiac symptoms or changing symptom patterns and positive ECG findings with normal biomarkers) 4) angiography-proven CHD, and 5) CHD death (any death in hospital due to CHD or sudden cardiac death caused by cardiac disease occurring ≤ 1 h after beginning of symptoms) [21]. Furthermore, CVD was clarified as a composite of CHD and cerebrovascular events [transient ischemic attack (TIA), ischemic or hemorrhagic stroke and cerebrovascular death]. To assess the relationship of newly detected abnormal glucose tolerance with the more severe form of cardiovascular events, hard CHD events were defined as the occurrence of nonfatal MI and CHD death and hard CVD event considered as nonfatal MI, nonfatal stroke and CVD death [22].

Statistical analysis
Little’s Missing Completely at Random (MCAR) test was used to check whether or not the missing data follow a completely random pattern [23]. The result showed that the missingness is not completely at random (P-value < 0.001). Therefore, for dealing with missing values, we used multiple imputations by chained equations (MICE) with 10 imputed data sets since ≈ 10% of cases were incomplete (2 h-PCPG, BMI, and low physical activity: ≈ 10%; other covariates: < 3%) [24, 25]. We obtained all estimates by averaging results across the imputed datasets.

Baseline characteristics are expressed as mean [standard deviation (SD)] and median [interquartile range (IQR)] for continuous variables with and without normal distributions, respectively and number (%) for categorical ones across the NFG, IFG and NDM. To compare the baseline characteristics in different glucose intolerance categories, ANOVA (or Kruskal–Wallis for variables with non-normal distribution) and chi-square tests were employed for continuous and categorical variables, respectively.

To be able to capture a potential nonlinear association between FPG/2 h-PCPG and incident CVD/CHD outcomes, restricted cubic splines with 4 knots defining the 5th, 25th, 75th, and 95th percentiles, were used. As shown in Fig. 2, we accepted the null hypothesis that outcome risks were a linear function of the FPG/2 h-PCPG.

Multivariable Cox proportional hazard models were used to evaluate associations of the different glucose intolerance categories with recurrent CVD, hard CVD, CHD, hard CHD and incident diabetes separately, using NFG-5.6 or NFG-6.1 or NGT as reference.

The survival time for CVD, CHD, and the related hard outcomes was defined as the time between the entered date and the event date. Additionally, for the censored participants (leaving the residential area, death, loss to follow-up or end of follow-up until 20 March 2016), the survival time was defined as the difference between the entered date and the last available follow-up date.

Regarding incident diabetes, the event date was defined as the date of incident diabetes or being censored (leaving the residential area, death, loss to follow-up, or end of follow-up until 20 March 2018); the date of the event was defined as the mid-time between the last observation date of without and with diabetes. Additionally, for the censored participants, the censored date was defined as the difference between the last observation date without diabetes.

For the Cox regression analysis, two models were designed: model 1 included sex and baseline measurements of age; in model 2, following potential risk factors based on the literature review [26] were added for
incident CVD/CHD: BMI, heart rate, family history of premature CVD (reference: no), hypertension (reference: no), high TC (reference: no), low HDL-C (reference: no), current smoking (reference: no), use of aspirin (reference: no), use of β-blocker (reference: no), and low physical activity (reference: no). Considering the outcome of incident diabetes, the literature review [27, 28] determined following potential risk factors to be included in model 2: BMI, family history of diabetes, low HDL-C (reference: no), high TG (reference: no), and low physical activity (reference: no).

The proportionality in the Cox model was evaluated with the Schoenfeld residual test and generally, all proportionality assumptions were appropriate. Statistical analysis was performed using STATA version 14 (Stata Corp LP, College Station, Texas) statistical software. P-values < 0.05 were considered statistically significant.

Results
Previous CVD in 408 subjects consisted of history of definite CAD (164), ACS (104), non-fatal MI (69), non-fatal stroke (56) CABG (10) and PCI (5) (Fig. 3). Baseline characteristics of study participants in different glucose tolerance categories according to ADA criteria are shown in Table 1. The mean (SD) age of total population was 60.6 (10.5) years and 58.3% were men. Generally, there were significant differences between different groups of glucose tolerance in BMI, WC, SBP, FPG, 2 h-PCPG, TC, triglycerides and low physical activity levels.

Over a decade of follow-up, 220 CVD including 89 hard events and 202 CHD including 58 hard events occurred. Among 361 subjects with prevalent CVD and free of diabetes at baseline, 141 incident diabetes occurred with an incidence rate of 38.88 (32.97–45.86) per 1000 persons-years.
Table 1  Baseline characteristics of the study population

|                          | Total population (n = 408) | NFG (n = 253) | IFG-ADA (n = 118) | NDM(n = 37) | P-Value | Statistics b |
|--------------------------|-----------------------------|---------------|-------------------|-------------|---------|--------------|
| Continuous variables, mean (SD) |                             |               |                   |             |         |
| Age (years)              | 60.6 (10.5)                 | 60.0 (10.9)   | 61.3 (10.2)       | 62.8 (8.7)  | 0.22    | 1.51         |
| BMI (kg/m²)              | 28.2 (4.7)                  | 27.6 (4.6)    | 29.0 (4.8)        | 29.2 (4.8)  | 0.009   | 4.82         |
| WC (cm)                  | 97.1 (10.5)                 | 95.6 (10.6)   | 99.2 (9.8)        | 100.7 (9.6) | 0.001   | 7.54         |
| SBP (mmHg)               | 130.7 (21.2)                | 128.4 (20.3)  | 132.8 (20.7)      | 139.2 (25.6) | 0.006   | 5.22         |
| DBP (mmHg)               | 78.4 (11.8)                 | 78.2 (12.2)   | 78.1 (11.4)       | 80.2 (9.6)  | 0.62    | 0.48         |
| HR (beats/minute)        | 76.7 (11.9)                 | 75.7 (12.0)   | 78.3 (12.1)       | 78.7 (9.9)  | 0.08    | 2.49         |
| FPG (mmol/L)             | 5.6 (1.4)                   | 5.0 (0.4)     | 6.1 (0.4)         | 9.1 (2.1)   | <0.001  | 555.01       |
| 2 h-PCPG (mmol/L)        | 8.2 (4.3)                   | 6.4 (1.8)     | 8.9 (2.6)         | 18.2 (5.8)  | <0.001  | 323.8        |
| HDL-C (mmol/L)           | 5.1 (1.1)                   | 5.3 (1.1)     | 5.4 (1.0)         | 5.8 (1.4)   | 0.04    | 3.25         |
| Triglycerides (mmol/L) a | 1.85 (1.24)                 | 1.8 (1.2)     | 1.8 (1.3)         | 2.4 (1.3)   | 0.04    | 4.23         |
| Categorical variables, n (%) |                             |               |                   |             |         |
| Gender (men)             | 238 (58.3)                  | 150 (59.3)    | 64 (54.2)         | 24 (64.9)   | 0.47    | 1.56         |
| Family history of CVD    | 62 (15.2)                   | 39 (15.4)     | 19 (16.1)         | 4 (10.8)    | 0.79    | 0.51         |
| Current smoking          | 69 (16.9)                   | 42 (16.6)     | 20 (16.9)         | 7 (18.9)    | 0.94    | 0.12         |
| Low physical activity    | 174 (42.6)                  | 114 (45.1)    | 53 (44.9)         | 7 (18.9)    | 0.007   | 9.37         |
| Hypertension             | 218 (53.4)                  | 131 (51.8)    | 66 (55.9)         | 21 (56.8)   | 0.69    | 0.74         |
| Hypercholesterolemia     | 245 (60.0)                  | 149 (58.9)    | 73 (61.9)         | 23 (62.2)   | 0.86    | 0.37         |
| Medications              |                             |               |                   |             |         |
| Anti-hypertensive medication | 133 (32.6)                  | 83 (32.8)     | 37 (31.4)         | 13 (35.1)   | 0.88    | 0.20         |
| Lipid-lowering medication | 45 (11.0)                   | 27 (10.7)     | 13 (11.0)         | 5 (13.5)    | 0.83    | 0.27         |
| Aspirin use              | 198 (48.5)                  | 129 (51.0)    | 49 (41.5)         | 20 (54.1)   | 0.17    | 3.38         |

Values are expressed as mean (SD) or median (interquartile range) for continuous variables and n (%) for categorical variables.

Missing values were imputed with multiple imputation. NFG normal fasting glucose, IFG impaired fasting glucose, NDM newly diagnosed diabetes, ADA American Diabetes Association, BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, FPG fasting plasma glucose, 2 h-PCPG 2 h post challenge plasma glucose, TC total cholesterol, HDL-C High density lipoprotein-cholesterol, CVD cardiovascular disease

a Median and interquartile range (IQR)

b ANOVA F statistics for continues variables and Pearson Chi-square or Fisher exact value for categorical variables. For Triglycerides Kruskal Wallis test was reported.
Outcome 1: recurrent CVD/CHD
Risks of adverse cardiovascular outcomes based on different glucose intolerance categories are illustrated in Tables 2 and 3. Considering the level of FPG, subjects with IFG using both WHO and ADA definitions had no statistically significant higher risk of CVD/CHD even in the age and sex adjusted model. Regarding hard outcomes, only IFG-ADA was associated with significantly higher risk of hard CVD in model 1 [hazard ratio (HR), 95% CI 1.62, 1.03–2.57] and showed a signal for the event in model 2 (HR, 95% CI 1.52, 0.95–2.45, p = 0.08). Subjects with NDM using FPG definition, in both IFG-WHO and IFG-ADA datasets, were at > two-fold higher risk of CVD (2.15, 1.41–3.27), hard CVD (2.41, 1.25–4.67).

Table 2: Multivariable adjusted risks of CVD and hard CVD based on different glucose intolerance categories. (n = 408)

| Glucose Category | CVD HR (95%CI) | Hard CVD HR (95%CI) |
|------------------|----------------|----------------------|
|                  | E/N Model 1    | Model 2              | E/N Model 1    | Model 2              |
| FPG-WHO (mmol/L) |                |                      |                |                      |
| < 6.1            | 169/327        | 1.00                 | 1.00           | 66/327               | 1.00                 |
| 6.1–6.9          | 21/44          | 0.92 (0.58–1.45)     | 0.87 (0.55–1.39) | 10/44               | 1.13 (0.58–2.21)     | 0.97 (0.49–1.93)     |
| ≥ 7              | 30/37          | 2.02 (1.36–3.00)     | 2.07 (1.39–3.12) | 13/37               | 1.95 (1.07–3.53)     | 2.02 (1.07–3.80)     |
| FPG-ADA (mmol/L) |                |                      |                |                      |
| < 5.6            | 129/253        | 1.00                 | 1.00           | 45/253               | 1.00                 |
| 5.6–6.9          | 61/118         | 1.07 (0.79–1.46)     | 1.05 (0.77–1.44) | 31/118               | 1.62 (1.03–2.57)     | 1.52 (0.95–2.45)     |
| ≥ 7              | 30/37          | 2.09 (1.40–3.12)     | 2.15 (1.41–3.27) | 13/37               | 2.28 (1.23–4.22)     | 2.41 (1.25–4.67)     |
| 2 h-PCPG (mmol/L)|                |                      |                |                      |
| < 7.8            | 123/240        | 1.00                 | 1.00           | 50/240               | 1.00                 |
| 7.8–11.0         | 54/105         | 1.01 (0.73–1.39)     | 0.97 (0.70–1.36) | 20/105               | 0.93 (0.55–1.56)     | 0.90 (0.53–1.55)     |
| ≥ 11             | 43/63          | 1.48 (1.04–2.10)     | 1.46 (1.02–2.11) | 19/63               | 1.59 (0.93–2.70)     | 1.54 (0.88–2.70)     |

Table 3: Multivariable adjusted risks of CHD and hard CHD based on different glucose intolerance categories. (n = 408)

| Glucose Category | CHD HR (95%CI) | Hard CHD HR (95%CI) |
|------------------|----------------|----------------------|
|                  | E/N Model 1    | Model 2              | E/N Model 1    | Model 2              |
| FPG-WHO (mmol/L) |                |                      |                |                      |
| < 6.1            | 156/327        | 1.00                 | 1.00           | 41/327               | 1.00                 |
| 6.1–6.9          | 19/44          | 0.89 (0.55–1.43)     | 0.83 (0.51–1.35) | 7/44                | 1.27 (0.57–2.84)     | 1.01 (0.44–2.32)     |
| ≥ 7              | 27/37          | 1.89 (1.25–2.87)     | 1.97 (1.28–3.03) | 10/37               | 2.31 (1.15–4.62)     | 2.56 (1.21–5.39)     |
| FPG-ADA (mmol/L) |                |                      |                |                      |
| < 5.6            | 120/253        | 1.00                 | 1.00           | 30/253               | 1.00                 |
| 5.6–6.9          | 55/118         | 1.04 (0.75–1.43)     | 1.02 (0.73–1.41) | 18/118               | 1.39 (0.77–2.49)     | 1.30 (0.71–2.40)     |
| ≥ 7              | 27/37          | 1.94 (1.27–2.97)     | 2.03 (1.30–3.16) | 10/37               | 2.50 (1.22–5.12)     | 2.84 (1.31–6.19)     |
| 2 h-PCPG (mmol/L)|                |                      |                |                      |
| < 7.8            | 112/240        | 1.00                 | 1.00           | 31/240               | 1.00                 |
| 7.8–11.0         | 51/105         | 1.02 (0.73–1.42)     | 1.00 (0.70–1.40) | 13/105               | 0.97 (0.51–1.85)     | 0.93 (0.47–1.83)     |
| ≥ 11             | 39/63          | 1.46 (1.01–2.11)     | 1.46 (1.00–2.15) | 14/63               | 1.91 (1.01–3.60)     | 1.95 (0.99–3.85)     |
1.25–4.67), CHD (2.03, 1.30–3.16) and hard CHD (2.84, 1.31–6.19) compared to subjects with NFG in the fully adjusted model.

Regarding 2 h-PCPG, subjects with IGT had no significantly higher risk of CVD/CHD and related hard outcomes compared to those with 2 h-PCPG < 7.8 mmol/L. Moreover, NDM (2 h-PCPG ≥ 11.0 mmol/L) was significantly associated with risk of CVD (1.46, 1.02–2.11), CHD (1.46, 1.00–2.15) and hard CHD (1.95, 0.99–3.85, \(P = 0.05\)) in model 2.

As shown in Table 4, when FPG is considered as a continuous variable, HRs (95% CI) associated with a 1 SD increase in FPG were 1.20 (1.08–1.34) for CVD, 1.27 (1.07–1.51) for hard CVD, 1.15 (1.02–1.29) for CHD and 1.25 (1.00–1.56) for hard CHD in the fully adjusted model; the corresponding values for 2 h-PCPG were 1.21 (1.07–1.36), 1.21 (0.99–1.47), \(P = 0.06\), 1.16 (1.03–1.32) and 1.23 (0.96–1.57), respectively. Moreover, when both FPG and 2 h-PCPG were entered in the same model, risk of CVD/CHD was not significant for these variables excluding for hard CVD events when higher values of FPG but not 2 h-PCPG was associated with marginally significant risk (Data not shown).

**Outcome 2: incident diabetes**

As shown in Table 5, both IFG-WHO [2.28 (1.44–3.63), \(p < 0.001\)] and IFG-ADA [2.37 (1.66–3.37), \(p < 0.001\)] were associated with significantly higher risk of incident diabetes in the fully adjusted model. Moreover, IGT was associated with > 2.5-fold higher risk in the fully adjusted model [2.67 (1.87–3.79), \(p < 0.001\)]. HRs (95% CI) per each 1-SD increase in FPG and 2 h-PCPG for incident diabetes in the fully adjusted model were 9.90 [(4.67–20.98), \(p < 0.001\)] and 2.79 [(2.05–3.79), \(p < 0.001\)], respectively.

**Sensitivity analyses**

To show the robustness of our findings, we additionally performed three sensitivity analyses. First, we repeated our analysis among subject with complete data (n = 301); the results were generally in line with

| Table 4 | Adjusted HR (95% CI) for adverse cardiovascular outcomes per 1-SD increase of FPG and 2 h-PCPG. (n = 408) |
| --- | --- | --- | --- | --- |
| | CVD | Hard CVD | CHD | Hard CHD |
| | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value |
| FPG | | | | | | | | |
| Model 1 | 1.21 (1.09–1.34) | < 0.001 | 1.27 (1.08–1.49) | 0.004 | 1.15 (1.03–1.29) | 0.01 | 1.22 (0.99–1.49) | 0.06 |
| Model 2 | 1.20 (1.08–1.34) | 0.001 | 1.27 (1.07–1.51) | 0.006 | 1.15 (1.02–1.29) | 0.02 | 1.25 (1.00–1.56) | 0.05 |
| 2 h-PCPG | | | | | | | | |
| Model 1 | 1.21 (1.08–1.36) | 0.001 | 1.21 (1.01–1.45) | 0.04 | 1.17 (1.03–1.32) | 0.01 | 1.20 (0.96–1.51) | 0.11 |
| Model 2 | 1.21 (1.07–1.36) | 0.002 | 1.21 (0.99–1.47) | 0.06 | 1.16 (1.03–1.32) | 0.02 | 1.23 (0.96–1.57) | 0.10 |

CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2 h-PCPG 2 h post challenge plasma glucose

Model 1: age and sex
Model 2: model 1 + body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity

| Table 5 | Risks of incident diabetes based on different glucose intolerance states. (n = 361) |
| --- | --- | --- | --- |
| | Model 1 | P value | Model 2 | P value |
| FPG and 2 h-PCPG categories | | | | |
| IFG-WHO | 2.79 | 1.78–4.37 | < 0.001 | 2.28 | 1.44–3.63 | < 0.001 |
| IFG-ADA | 2.46 | 1.75–3.46 | < 0.001 | 2.37 | 1.66–3.37 | < 0.001 |
| IGT | 2.94 | 2.09–4.12 | < 0.001 | 2.67 | 1.87–3.79 | < 0.001 |
| Per 1-SD increase | | | | |
| FPG | 12.82 | 6.18–26.60 | < 0.001 | 9.90 | 4.67–20.98 | < 0.001 |
| 2 h-PCPG | 3.20 | 2.39–4.29 | < 0.001 | 2.79 | 2.05–3.79 | < 0.001 |

HR hazard ratio, CI confidence interval, IFG impaired fasting glucose, IGT impaired glucose tolerance, WHO World Health Organization, ADA American Diabetes Association, FPG fasting plasma glucose, 2 h-PCPG 2 h post challenge plasma glucose

Model 1: age and sex
Model 2: model 1 plus family history of diabetes, body mass index, low physical activity, hypertriglyceridemia and low HDL-C
the imputed dataset; however, in complete case analysis, NDM (FPG ≥ 7 mmol/L) was only associated with CVD/CHD but not hard outcomes and NDM (2 h-PCPG ≥ 11.0 mmol/L) was not a risk for any cardiovascular outcome. Moreover, each 1 SD increase in FPG and 2 h-PCPG was only associated with CVD/CHD (Additional file 1: Tables S1 and S2). Second, we analyzed data after exclusion of those who stroke at baseline (n = 56) and also in patients with definite CAD; results were generally in agreement with main findings (Additional file 1: Tables 3, 4 and 5). Third, to compare our findings with those of other studies, we defined abnormal glucose tolerance (AGT) as 2 h-PCPG ≥ 7.8 mmol/L versus 2 h-PCPG < 7.8 mmol/L (reference group). Accordingly, AGT similar to IGT was not associated with any cardiovascular outcome (Data not shown).

Discussion
Findings of this population-based cohort study among subjects with stable CVD without known diabetes over a decade of follow-up are summarized as follows: Firstly, for FPG, IFG-ADA was associated with more than 60% higher risk of hard CVD events only in the age and sex adjusted model; however, NDM was associated with higher risk of recurrent CVD/CHD and their related hard outcomes, independent of traditional risk factors. Likewise, every 1.04 mmol/L increase in FPG was associated with 20, 27, 15 and 25% higher risk of CVD, hard CVD, CHD and hard CHD, respectively. Secondly, regarding 2 h-PCPG, subjects with NDM had 46% increased risk of CVD and CHD and 95% higher risk of hard CHD. Moreover, every 3.49 mmol/L increase in 2 h-PCPG was associated with 21% and 16% higher risk of CVD and CHD, respectively. Thirdly, FPG and 2 h-PCPG, whether as continuous or categorical variables were significant predictors of incident diabetes.

Abnormal glucose tolerance and recurrent cardiovascular events
Impact of IFG, IGT and NDM on recurrent cardiovascular outcomes has been addressed in previous studies; however, two important issues should be noted: First, most of these studies were performed in the hospital setting among patients with a high baseline risk for recurrent events i.e., those with MI [11, 12, 29–33], or PCI/CABG [10]. Second, there were great differences between studies in terms of sample size, follow-up duration, approaching FPG and 2 h-PCPG as a continuous or categorical variable and heterogeneity in outcome definitions (CVD, MACE, all-cause or cardiovascular mortality). To our knowledge, the present study is the first population-based cohort with a long-term follow-up to investigate these associations in a heterogenic and relatively low risk population with stable CVD.

Findings of previous studies regarding the association of FPG with recurrent CVD were inconsistent. FPG as a continuous variable was not associated with recurrent CV outcomes [9, 10, 34] or had a borderline lower risk of recurrent CVD (0.85, 0.71–1.01, p = 0.06) [30, 35]; whereas each 1 mmol/L increase in FPG was associated with higher risk of MACE (28%) and cardiovascular mortality (51%) among post-MI patients in UK, hazards were not significant in the models including both FPG and 2 h-PCPG [36]. Our results showed that increasing level of FPG was significantly associated with higher risk of CVD/CHD; however, when both FPG and 2 h-PCPG were included in the model, no association was demonstrated.

With regards to the use of standard cut-offs among patients with prevalent CAD, IFG-WHO was not associated with MACE in the study by Tamita [HR 1.86 (0.86–3.87)] [12], any cardiac outcomes in the ARTEMIS study [9] and composite endpoints (including cardiovascular mortality, non-fatal MI, stroke, or hospitalization for heart failure) in the EUROASPIRE IV study [10]. Furthermore, in a population-based study among Japanese men, borderline hyperglycemia (FPG = 5.6–6.9 mmol/L) was not associated with recurrent CVD outcomes among those with prior CAD [37]. Similarly, prediabetes (using FPG and HbA1C criteria) was not associated with CV outcomes in Chinese patients [38, 39]. Besides, Lenzen et al. [40] revealed that abnormal glucose regulation (AGR) (IFG and IGT) was not an independent predictor for hard CV outcomes in the hospital-based setting while AGR in men with HF was associated with significant higher risk of recurrent CV outcomes [13]. The Otten et al. [41] study showed that IFG-ADA was associated with a hazard of 1.66 (1.05–2.61) for MACE. Based on our findings, among patients with stable CVD at an outpatient setting, IFG-ADA showed a signal for the association with hard CVD outcome, the value which did not reach to the significant level. Importantly, we have recently reported that the significant risk of IFG for CVD events in general population is attributable to those who converted from the IFG state to diabetes [42]; unfortunately, the current study did not have an adequate power to test this possibility in a cohort of subjects with previous CVD.

Focusing on 2 h-PCPG, some studies suggest that 2 h-PCPG is a better determinant to assess the prognosis of post ACS patients compared to FPG. Notably, some authors believe that adding 2 h-PCPG (but not FPG) to the Global Registry of Acute Coronary Events (GRACE) score (an established risk model for recurrent cardiac events), can improve its prediction power in post MI.
patients without known diabetes [30, 35]. Similarly, Chat-topadhyay et al. showed that 2 h-PCPG is a better predictor of adverse post MI outcomes compared to FPG [36]. In this regard, our study showed a significant positive association between 2 h-PCPG and recurrent CVD/CHD outcomes. In some but not all studies, IGT was associated with worse post MI prognosis [10, 30, 34]. George et al. revealed that IGT is associated with higher risk of MACE but not hard CVD outcomes [31]. In line with studies among low risk population with prevalent CAD [9, 43], we also found no risk of IGT for recurrent CVD/CHD.

Regarding NDM, we found that NDM using FPG criteria was associated with CVD/CHD and their related hard outcomes. Among Chinese patients who underwent PCI, NDM (using FPG or HbA1C criteria) was an independent risk factor for MACE but not hard outcomes [38]. In the George et al. study, NDM (using FPG and/or 2 h-PCPG criteria) was associated with CVD and related hard outcomes [31]. However, in large studies conducted on European populations [10, 40], NDM was not associated with CVD outcomes. Using 2 h-PCPG criteria for definition of NDM, most studies showed that NDM [29, 34] or AGT (NDM plus IGT) are independently associated with higher risk of different CV outcomes [10–12, 32–34]; these findings are in agreement with ours indicating significant associations of NDM using 2 h-PCPG criteria with CVD, CHD and hard CHD.

Incident diabetes outcome

History of CVD is known as a risk factor of incident diabetes among overweight and obese population [28]; however, it was not an independent risk factor for incident diabetes among Iranian population [44]. The present study showed that both FPG and 2 h-PCPG are strong independent predictors of incident diabetes. While in the EUROASPIRE IV study, 2 h-PCPG but not FPG, was a significant predictor [10], in the ARTEMIS study [9], both IGT and IFG groups had similarly higher risk for incident diabetes compared with the normoglycemia group.

Strengths and limitations

Strengths of the current study are its prospective, longitudinal design with a long-term follow-up, reliable measurements of different covariates and careful adjustment for potential confounders. Moreover, our study included a heterogenous group of subjects with history of CAD in the stable phase of the disease and evaluated a wide range of outcomes including hard CVD/CHD events. The study limitations should also be considered: Firstly, we did not have data to calculate GRACE score including the ejection fraction of subjects; however, available variables of this score system such as heart rate were included in the multivariable model. Secondly, serum HbA1c levels were not available which may cause misclassification and underestimation of the risk associated with prediabetes; however, some well-known cohorts including Framingham Offspring Study have investigated associations of glycemic states with CV outcomes without HbA1c measurement [45]. Third, in our population based study, routine cardiac biomarkers were applied for diagnosis of MI (see definition of terms) in general hospitals. However, other promising investigational biomarkers such as high sensitivity c-Tn (hs-cTn), plasma asymmetric dimethylarginine (ADMA) and heart-type fatty acid binding protein (H-FABP) with a potential role in diagnosis of ACS [46, 47] or in the pathogenesis of restenosis were not assessed [48]. Fourth, data about diet were not available at the baseline recruitment of the study. Finally, this study was conducted on an Iranian urban population and the findings cannot be extrapolated to the rural areas.

Conclusions

Among subjects with stable CVD, although increasing levels of FPG and 2 h-PCPG were associated with significant risk of recurrent CVD/CHD, only NDM but not prediabetes status was a significant risk factor for recurrent events. Moreover, FPG and 2 h-PCPG, as either continuous or categorical variables were significantly associated with incident diabetes.

Abbreviations

CVD: Cardiovascular disease; CHD: Coronary heart disease; NFG: Normal fasting glucose; NGT: Normal glucose tolerance; IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance; NDM: Newly diagnosed diabetes; HR: Hazard ratio; CI: Confidence interval; SD: Standard deviation; MENA: Middle East and North Africa; TLGS: Tehran Lipid and Glucose Study; FPG: Fasting plasma glucose; 2 h-PCPG: 2 h post challenge plasma glucose; BMI: Body mass index; WC: Waist circumference; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TC: Total cholesterol; HDL-C: High density lipoprotein-cholesterol; ECG: Electrocardiogram; ADA: American Diabetes Association; WHO: World Health Organization; MI: Myocardial infarction.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12967-021-02950-y.

Additional file 1: Table S1. Risks of adverse cardiovascular outcomes based on different glucose intolerance categories. (complete case, n=301).

| Table S2. | Adjusted HR (95% CI) for adverse cardiovascular outcomes per 1-SD increase of FPG and 2h-PCPG. (complete case, n=301). |
|-----------|---------------------------------------------------------------------------------------------------------------------------|
| Table S3. | Risks of adverse cardiovascular outcomes based on different glucose intolerance categories. (after excluding stroke from CVD definition, n=352). |
| Table S4. | Adjusted HRs (95% CI) for adverse cardiovascular events per 1-SD increase of FPG and 2h-PCPG. (after excluding stroke from CVD definition, n=352). |
| Table S5. | Adjusted HR (95% CI) for adverse cardiovascular outcomes per 1-SD increase of FPG and 2h-PCPG among those with definite CAD. (n=164). |
Acknowledgements
We would also like to express our appreciation to the research team members and to TLGS participants for their enthusiastic support. The authors wish to acknowledge Dr. Fatemeh Moosaie for critical editing of English grammar and syntax of the manuscript.

Authors’ contributions
FH, MK, and FA conceived and planned the study. SA conducted the analyses. MK, MGH, and FH developed the first draft of the manuscript. HA critically appraised the manuscript. All authors contributed to the writing of the paper and have read and approved the final manuscript. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
All data and materials are available upon request.

Declarations

Ethics approval and consent to participate
All participants gave written informed consents according to the Helsinki Declaration guideline and the study was approved by local ethics committee (medical ethics committee of the Research Institute for Endocrine Sciences).

Consent for publication
All authors have declared their consent for this publication.

Competing interests
None declared.

Author details
1Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 2Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No. 24, Yamen Street, Velenjak, P.O. Box: 19395-4763, Tehran, Iran. 3Department of Internal Medicine, Taleghani Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 14 February 2021 Accepted: 18 June 2021 Published online: 30 June 2021

References:
1. Khalli D, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study. PLoS ONE. 2014;9:e105804.
2. Wilson PW, D’Agostino RB Sr, Buring JE, Rifai N. Framingham heart study: the future of mortality risk prediction. Eur Heart J. 2005;26:3–9.
3. Barbieri U, D’Acunzo F, Nijhoff F, Moretti C, Biondi-Zoccai G, Mennuni M, Barbero U, D’Ascenzo F, Nijhoff F, Moretti C, Biondi-Zoccai G, Mennuni M, Azizi F, Mirbolouk M, Saadat N, Azizi F. Pre-diabetes tsunami: incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up. Diabet Med. 2017;34:69–78.
4. El-Sayed A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F, Sex-specific incidence rates and risk factors of premature cardiovascular disease: a long term follow up of the Tehran Lipid and Glucose Study. Int J Cardiol. 2017;227:826–32.
5. Barchik M, Malmberg K, Hamsten A, Edefors O, Norhammar AM, Silveira A, Tenser Å, Ohvrijuk J, Rydén L. Abnormal glucose tolerance—a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med. 2004;256:288–97.
6. Kivimäki AM, Lepojarvi ES, Tulppo MP, Pira O-P, Kettunen J, Perikkomäki JS, Ukkola OH, Myerburg RJ, Junttila MJ, Hukkuri H. Pre-diabetes and risk for cardiac death among patients with coronary artery disease: the ARTEMIS study. Diabetes Care. 2019;42:1319–25.
7. Shahim B, De Bacquer D, De Bacquer G, Gibey V, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Rydén L. The prognostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with cardiovascular disease: a report from EURASPIRE IV: a survey from the European Society of Cardiology. Diabetes Care. 2017;40:1233–40.
8. Tani T, Katayama T, Akasaka T, Yamamuro A, Kaji S, Moriga K, Kihara Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J. 2007;71:854–61.
9. Tani T, Katayama T, Yamamuro A, Kaji S, Yoshikawa J, Furukawa Y. Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations. Heart. 2012;98:848–54.
10. Thraïnisdóttir IS, Aspelund T, Hardarson T, Malmberg K, Sigurdsson G, Thorgersson G, Gudnason V, Rydén L. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Prev Cardiol. 2005;12:465–71.
11. Rydén L, Shahim B, Standl E. On the prognostic value of post-load glucose in patients with coronary artery disease. European heart journal 2018.
12. Mehrpour Z, Fattahi Z, Behehshtian M, Mohseni M, Pousshi H, Ardalan F, Jalalvand K, Arzhangi S, Mohammadi Z, Khoshabkhait S. Distinct genetic variation and heterogeneity of the iranian population. PLoS Genet. 2019;15:e1008385.
13. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Miriran P, Hedayati M, Mehrabi Y, Zahedi-Asl S. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5.
14. Association OD. Standards of Medical Care in Diabetes—2020 abridged for primary care providers. Clin Diab. 2020;38:10–38.
15. Organization WH. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. World Health Organization; 2011.
16. Sardarinia M, Akbarpour S, Lotfaliany M, Bagherzadeh-Khiabani F, Bozorgmanesh M, Sheikholeslami F, Azizi F, Hadaegh F. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a middle eastern population over a decade follow-up. Tehran lipid and glucose study. PLoS ONE. 2016;11, 2016.
17. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes. Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil. 2006;13:571–7.
18. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention, AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543–9.
23. Little RJ. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc. 1988;83:1198–202.

24. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377–99.

25. Steyerberg EW. Clinical prediction models. Springer; 2019.

26. Asgarí S, Barzin M, Hosseinpahan F, Hadaegh F, Azizi F, Khalili D. Obesity paradox and recurrent coronary heart disease in a population-based study: Tehran lipid and glucose study. International journal of endocrinology and metabolism 2016, 14.

27. Derakhshan A, Sardarinia M, Khalili D, Momennan AA, Azizi F, Hadaegh F. Sex-specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and Glucose Study. PloS ONE. 2014;9:e102563.

28. Association AD. 2 Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diab Care. 2021;44:S1–33.

29. Kitada S, Otsuka Y, Kokubu N, Kasahara Y, Kataoka Y, Noguchi T, Goto Y, Kimura G, Nomori H. Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc Diabetol. 2010;9:1–9.

30. Chattopadhyay S, George A, John J. Sathyapalan T. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. Diab Vasc Dis Res. 2019;16:489–97.

31. George A, Bhatia RT, Buchanan GL, Whiteside AJ, Mealsey S, Beer SF, Chattopadhyay S, John J, Sathyapalan T. Pre-diabetes mellitus newly diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PloS One 2015, 10.

32. Derakhshan A, Sardarinia M, Khalili D, Momennan AA, Azizi F, Hadaegh F. Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart. 2009;91:1466–8.

33. Kabootari M, Hasheminia M, Azizi F, Mirbolouk M, Hadaegh F. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study. Cardiovasc Diabetol. 2020;19:1–11.

34. Knudsen EC, Seljeffot I, Abdelnour M, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen GB. Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study. BMC Endocr Disord. 2011;11:1–14.

35. Otten R, Kline-Rogers E, Meier D, Dumasa R, Fang J, May N, Resin Y, Armstrong D, Saab F, Petrini M. Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart. 2005;91:1466–8.

36. Wang H, Song Y, Tang X, Ju J, Jiang P, Jiang L, Gao Z, Chen J, Song L, Zhang Y. Impact of unknown diabetes and prediabetes on clinical outcomes in “Nondiabetic” Chinese Patients: After A Primary Coronary Intervention. Nutrition, Metabolism and Cardiovascular Diseases 2019.

37. Yuan D, Zhang C, Ji S, Jiang L, Xu L, Zhang Y, Xu J, Xu B, Hui R, Gao R. Prediabetes and long-term outcomes in patients with three- vessel coronary artery disease: A large single-center cohort study. J Diab Invest. 2021;12:409–16.

38. Lenzen M, Ryden L, Ohvik J, Bartnik M, Malmberg K. Scholte op Reimer W, Simoons ML. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006;27:2969–74.

39. Otten R, Kline-Rogers E, Meier D, Dumasa R, Fang J, May N, Resin Y, Armstrong D, Saab F, Petrini M. Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart. 2005;91:1466–8.

40. Kabootari M, Hasheminia M, Azizi F, Mirbolouk M, Hadaegh F. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study. Cardiovasc Diabetol. 2020;19:1–11.

41. Knudsen EC, Seljeffot I, Abdelnour M, Eritsland J, Mangschau A, Müller C, Arnesen H, Andersen GB. Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study. BMC Endocr Disord. 2011;11:1–14.

42. Derakhshan A, Sardarinia M, Khalili D, Momennan AA, Azizi F, Hadaegh F. Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and Glucose Study. PloS one 2014, 9.

43. Meigs JB, Nathan DM, D’Agostino RB, Wilson PW. Fasting and post-challenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845–50.

44. Agenllo L, Bellia C, Scacchi C, Bivona G, Iacolino G, Gambino CM, Mura- tore M, Lo Sasso B, Ciaccio M. Establishing the 99th percentile for high sensitivity cardiac troponin I in healthy blood donors from Southern Italy. Biochimica medica. 2019;29:402–6.

45. Bivona G, Agenllo L, Bellia C, Sassò BL, Ciaccio M. Diagnostic and prognostic value of H-FABP in acute coronary syndrome: Still evidence to bring. Clin Biochem. 2018;58:1–4.

46. Zinellu A, Sotgia S, Porcu P, Casu MA, Bivona G, Chessa R, Deiana L, Caru C. Cardiac restenosis is associated with plasma ADMA concentration in carotid endarterectomy patients. Clin Chem Lab Med (CCLM). 2011;49:897–901.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.